Ono Pharmaceutical ADR Representing 1/3rd Ord Shs (OPHLY) – tečaj delnic in novice

Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948. Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb. In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia

Vizitka: Ono Pharmaceutical ADR Representing 1/3rd Ord Shs

Generalni direktorGyo Sagara | Gyo Sagara

Št. zaposlenih4,21 tis.

Ustanovljeno1717

SedežOsaka, Prefektura Osaka, Japonska

Sektor-

Spletno mestoono-pharma.com

Vse vrednosti v valuti JPY	sep. 2025	dec. 2025	mar. 2026	jun. 2026
Prihodek	129,60 mrd.	139,90 mrd.	118,75 mrd.	116,16 mrd.
Strošek prodanega blaga	34,96 mrd.	36,68 mrd.	33,06 mrd.	28,68 mrd.
Stroški materiala in storitev	34,96 mrd.	36,68 mrd.	33,06 mrd.	28,68 mrd.
Stroški raziskav in razvoja	34,77 mrd.	33,53 mrd.	42,49 mrd.	32,40 mrd.
Skupni stroški raziskav in razvoja	-	-	-	-
Stroški prodaje, splošni in administrativni stroški	30,08 mrd.	31,73 mrd.	27,70 mrd.	23,90 mrd.
Operativni strošek	64,56 mrd.	67,00 mrd.	77,09 mrd.	56,83 mrd.
Skupni operativni stroški	99,53 mrd.	103,68 mrd.	110,15 mrd.	85,51 mrd.
Prihodek iz poslovanja	30,07 mrd.	36,22 mrd.	8,60 mrd.	30,65 mrd.
Drug prihodek, ki ne izhaja iz poslovanja	-	-	318,00 mio.	−2,00 mio.
Zaslužek pred obdavčitvijo z vključenimi izrednimi postavkami	29,52 mrd.	37,20 mrd.	3,28 mrd.	31,25 mrd.
Zaslužek pred obdavčitvijo brez izrednih postavk	29,52 mrd.	37,20 mrd.	8,77 mrd.	31,25 mrd.
Odhodek iz obdavčitve dobička	7,17 mrd.	8,31 mrd.	2,24 mrd.	7,09 mrd.
Dejanska davčna stopnja	24,30 %	22,35 %	68,23 %	22,68 %
Drugi operativni stroški	−291,00 mio.	1,73 mrd.	3,81 mrd.	526,00 mio.
Čisti prihodek	22,42 mrd.	28,86 mrd.	818,00 mio.	24,15 mrd.
Neto stopnja dobička	17,30 %	20,63 %	0,69 %	20,79 %
Čisti dobiček na delnico	-	-	-	-
Prihodki iz obresti in naložb	677,00 mio.	1,39 mrd.	195,00 mio.	1,38 mrd.
Obrestni odhodki	−1,23 mrd.	−408,00 mio.	−34,00 mio.	−783,00 mio.
Neto obrestni odhodki	−549,00 mio.	979,00 mio.	161,00 mio.	598,00 mio.
Stroški amortizacije	-	-	3,10 mrd.	-
EBITDA	39,39 mrd.	45,82 mrd.	18,21 mrd.	39,63 mrd.
Dobiček ali izguba pri prodaji sredstev	-	-	2,20 mrd.	-

Vprašajte kar koli